Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction
Open Access
- 15 April 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (8) , 3037-3041
- https://doi.org/10.1182/blood-2002-09-2888
Abstract
Studies associating the prothrombin 20210G>A (FII 20210A), factor V Leiden (FVL), and factor XIII Leu34 (FXIII-A Leu34) alleles with myocardial infarction (MI) have yielded conflicting results. Complicated gene-gene interactions, small sample sizes, and heterogeneous genetic and environmental backgrounds may contribute to opposing findings. Simultaneous analysis of multiple gene variants in a large sample size from a genetically isolated population may overcome these weaknesses. Genotyping was performed in 500 MI patients and 500 control subjects from the genetically isolated Newfoundland population to determine the prevalence of the FII 20210A, FVL, and FXIII-A Leu34 variants and their association with MI. Gene-gene interactions were also analyzed. The prevalence of the FII 20210A allele was higher in MI patients (3.2%) than in control subjects (1.0%;P = .015). The FII 20210A allele was also 5.6-fold higher in MI patients younger than 51 years than in age-matched control subjects (P = .04). FVL showed 3.9-fold higher prevalence in young patients than in patients older than 50 years (P = .004) and 2.7-fold higher than in age-matched control subjects (P = .007). Furthermore, the prevalence of combined carriers of the FXIII-A L34 and FII 20210A alleles was 12-fold higher in MI patients than in control subjects (P = .002) and with 92% penetrance. There was disequilibrium of the FXIII-A Leu34 allele to MI patients carrying the FII 20210A allele as a genetic background. Based on our data, we determined that (1) the FII 20210A allele is a risk factor for MI, possibly important for early onset; (2) FVL may predispose for early-onset MI; (3) the FXIII-A Leu34 allele predisposes for MI in males only; however, (4) interaction between the FII 20210A and FXIII-A Leu34 alleles forms a synergistic coeffect that strongly predisposes for MI, placing combined carriers at high risk for MI.Keywords
This publication has 24 references indexed in Scilit:
- Factor XIIIA Val34Leu Polymorphism Does Not Predict Risk of Coronary Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Born to clot: the European burdenBritish Journal of Haematology, 1999
- Interaction of Coagulation Defects and Cardiovascular Risk FactorsCirculation, 1998
- Prevalence of the prothrombin gene variant 20210 G→A among patients with myocardial infarctionCardiovascular Research, 1998
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy MenNew England Journal of Medicine, 1995
- Premature ischaemic heart disease and the gene for coagulation factor VNature Medicine, 1995
- Myocardial infarction, Arg 506 to Gin factor V mutation, and activated protein C resistanceThe Lancet, 1995
- Resistance to Activated Protein C as a Basis for Venous ThrombosisNew England Journal of Medicine, 1994
- A simple salting out procedure for extracting DNA from human nucleated cellsNucleic Acids Research, 1988
- Persistent genetic isolation in outport NewfoundlandAmerican Journal of Medical Genetics, 1987